Table 1.
Expression of TCF7L2 assay ex13-13b and neurohormone genes
| Tissue | TCF7L2 ex13-13b | ex13-13b (fold vs pancreas) | CART | CHRA | NPY | GHRE | VIP | AGRP | SST | POMC | GIP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Thalamus | −4.25 | 750 | −6.13 | −4.50 | −2.67 | −12.83 | −8.58 | −14.49 | −4.55 | ND | ND |
| Occipital lobe | −5.42 | 333 | −5.15 | −0.23 | −1.00 | −10.97 | −2.80 | −12.75 | −0.86 | ND | ND |
| Hypothalamus | −6.49 | 159 | −6.06 | −5.57 | −3.98 | −13.39 | −8.58 | ND | −2.94 | ND | ND |
| Cerebellum | −7.82 | 63 | −5.13 | −6.53 | −8.85 | −12.74 | −8.64 | −11.73 | −14.85 | ND | ND |
| Pituitary gland | −8.58 | 37 | −9.15 | −0.33 | ND | −13.76 | −14.13 | ND | −10.74 | ND | ND |
| SHS5Y5 neuroblastoma cell line | −8.75 | 33 | −10.50 | NT | NT | NT | NT | NT | NT | NT | NT |
| Hippocampus | −8.99 | 28 | −6.57 | −3.51 | −3.85 | −10.85 | −6.68 | −13.05 | −5.54 | ND | −14.76 |
| Small intestine | −11.36 | 5.4 | −9.49 | −3.83 | −7.02 | −9.26 | −7.01 | ND | −5.83 | ND | −6.91 |
| Pancreatic islets | −11.84 | 3.9 | −12.05 | 0.76 | −3.14 | −5.79 | −11.48 | −16.50 | 3.29 | −13.18 | ND |
| Colon tumour | −13.24 | 1.5 | −10.90 | −9.47 | ND | ND | −8.13 | ND | −14.09 | ND | ND |
| Colon | −13.84 | 1.2 | −10.77 | −6.04 | −10.98 | ND | −6.80 | ND | −8.14 | ND | ND |
| Pancreas | −13.80 | 1.0 | −11.95 | −3.31 | −7.27 | −11.12 | −7.62 | ND | −2.59 | ND | ND |
| Correlation (r) | – | 0.85 | 0.21 | 0.66 | −0.57 | 0.10 | 0.45 | 0.11 | NS | NS | |
| p value | 0.00046* | NS | 0.06 | NS | NS | NS | NS |
Expression values are normalised to endogenous controls B2M and PPIA. Pearson’s correlation coefficients (r) are for expression of TCF7L2 assay ex13-13b and each neurohormone
Each tissue is represented by one sample or a pool of samples from two or three individuals; expression of assay ex13-13b was not detected in the following tissues: liver, lung, spleen, kidney, skeletal muscle, heart, blood, monocytes, lymphoblasts, breast, parotid, thyroid, ovary, oesophagus, stomach, bladder, prostate, ovarian cancer, lung cancer, kidney cancer, breast cancer, adipose and in NCI-60 cell lines and additional cell lines 293T, HepG2, HeLa, MDA435, MCF10, PANC1, SK-N-MC, prostate cell lines OPCN1, OPCN2, OPCN3, OPCT1, OPCT2, OPCT3, RWPE-1, RWPE-2, PWR1E, bladder cancer cell lines HTB-5, HTB-9, HT-1376 and J-82
*p value will be significant even after adjustment for multiple tests
ND, expression tested but not detected; NS, no significant correlation based on samples with detectable expression for both assays; NT, expression not tested